Avonex 30 mcg in 0.5 mL Auto-Injector
RxNorm 1650901
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1650901 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Avonex 30 mcg in 0.5 mL Auto-Injector.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SYPrescribable
Synonym (SY):
0.5 mL Avonex 0.06 mg/ML Auto-Injector
(Atom ID: 7240600)
SBDPrescribable
Semantic Branded Drug (SBD):
0.5 mL interferon beta-1a 0.06 mg/ML Auto-Injector [Avonex]
(Atom ID: 12371373)
PSNPrescribable
Prescribable Name (PSN):
Avonex 30 mcg in 0.5 mL Auto-Injector
(Atom ID: 7240599)
SYPrescribable
Synonym (SY):
Avonex 30 mcg per 0.5 mL Auto-Injector
(Atom ID: 7240601)
Patient Education
Interferon Beta-1a Intramuscular Injection
Interferon beta-1a intramuscular injection is used to treat adults with various forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control) including: clinically isolated syndrome (CIS; nerve symptom episodes that last at least 24 hours), relapsing-remitting forms (course of disease where symptoms flare up from time to time), or secondary progressive forms (course of disease where relapses occur more often). Interferon beta-1a is in a class of medications called immunomodulators. It works by decreasing inflammation and preventing nerve damage that may cause symptoms of multiple sclerosis.
[Learn More]
Interferon Beta-1a Subcutaneous Injection
Interferon beta-1a subcutaneous injection is used to treat adults with various forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control) including: clinically isolated syndrome (CIS; nerve symptom episodes that last at least 24 hours), relapsing-remitting forms (course of disease where symptoms flare up from time to time), or secondary progressive forms (course of disease where relapses occur more often). Interferon beta-1a is in a class of medications called immunomodulators. It works by decreasing inflammation and preventing nerve damage that may cause symptoms of multiple sclerosis.
[Learn More]
* Please review the disclaimer below.
